Khaja Moinuddin, MA Altaf, Githa kishore
1 Department of Pharmacy Practice, Viveswarapura Institute of Pharmaceutical Sciences, Bangalore. 1. Department of Pharmaceutics, IBNSINA National medical college, Jeddah KSA 2. Department of Pharmacy Practice, Viveswarapura Institute of Pharmaceutical Sciences, Bangalore.
Keywords: Pediatrics; Pneumonia; Antibiotics.

Pneumonia is a lower respiratory tract infection that specially affects the lungs and is caused by micro-organisms. Pneumonia kills more children than any other illness, more than AIDS, malaria and measles combined. To study the prescribing pattern of antibiotics in pneumonia in pediatric patients. A prospective study was conducted for nine months in inpatients of pediatric department of KIMS hospital and research centre, Bangalore. The review of treatment charts, patient’s parents/caregiver interview was conducted to collect the data pertaining to study of prescribing pattern of antibiotics used in the treatment of pneumonia. The collected data was analyzed by the descriptive statistical analysis. In this study, out of 105 patients 62 were males and 43 females.(43%) of inpatients were less then one year in age and 72 patients were not completely immunized. 61 patient diagnosed as pneumonia representing consolidation and 44 with bronchopneumonia. 43% Amox-clav and i.v Ceftriaxone 36% were commonly prescribed antibiotic pneumonia. 73 patients prescribed with single antibiotic. 54% Ceftriaxone was prescribed as empirical antibiotic. Pneumonia is most commonly seen in children who were with incompletely immunized. More male children suffered from pneumonia than females. The most commonly prescribed antibiotic was i.v Amox-clav in patients representing consolidation and i.v Ceftriaxone in bronchopneumonia. Ceftriaxone was the commonly prescribed as empirical antibiotic. Patients who received therapy with cephalosporin derivatives (Ceftriaxone and cefotaxime) had the lower mean duration of hospital stay, less than 7 days

Article Information

Identifiers and Pagination:
First Page:204
Last Page:211
Publisher Id:JAppPharm (2012 ). 4. 204-211
Article History:
Received:April 12, 2012
Accepted:May 27, 2012
Collection year:2012
First Published:July 1, 2012

© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany


Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885